Methadone metabolites (EDDP) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-229-Ag01	BSA-Methadone metabolites (EDDP)	756
GMP-SMT-229-Ag02	OVA-Methadone metabolites (EDDP)	756
GMP-SMT-229-Ab01	Anti-human Methadone metabolites (EDDP) mouse monoclonal antibody (mAb)	1953
GMP-SMT-229-Ab02	Anti-human Methadone metabolites (EDDP) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-229-Ag01
Product Name	BSA-Methadone metabolites (EDDP)
Target/Biomarker	Methadone metabolites (EDDP)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Methadone metabolites (EDDP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EDDP level test of Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methadone metabolites (EDDP) / OVA-Methadone metabolites (EDDP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-229-Ag02
Product Name	OVA-Methadone metabolites (EDDP)
Target/Biomarker	Methadone metabolites (EDDP)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Methadone metabolites (EDDP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EDDP level test of Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methadone metabolites (EDDP) / OVA-Methadone metabolites (EDDP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-229-Ab01
Product Name	Anti-human Methadone metabolites (EDDP) mouse monoclonal antibody (mAb)
Target/Biomarker	Methadone metabolites (EDDP)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Methadone metabolites (EDDP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EDDP level test of Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methadone metabolites (EDDP) / OVA-Methadone metabolites (EDDP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-229-Ab02
Product Name	Anti-human Methadone metabolites (EDDP) human monoclonal antibody (mAb)
Target/Biomarker	Methadone metabolites (EDDP)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Methadone metabolites (EDDP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EDDP level test of Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Methadone metabolites (EDDP) / OVA-Methadone metabolites (EDDP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

1. Introduction to Methadone Metabolites in In Vitro Diagnosis (IVD) Methadone, a potent opioid medication, is indispensable in pain management and opioid addiction treatment. In the realm of in vitro diagnosis (IVD), Methadone metabolites emerge as critical players, shedding light on the intricate processes governing Methadone metabolism within the human body. This comprehensive exploration delves into the multifaceted role of Methadone metabolites within IVD, elucidating their crucial applications, methodologies, and the profound significance of their measurement. 2. The Significance of Methadone Metabolites in IVD Methadone metabolites serve as invaluable biomarkers, offering profound insights into Methadone therapy's dynamics. They enable a precise understanding of how the body processes Methadone and its associated metabolites. By scrutinizing Methadone metabolite levels within patient samples, IVD facilitates precise treatment monitoring and optimization, enhancing the therapeutic outcomes of Methadone-based interventions. 3. Assessment of Treatment Efficacy Quantifying Methadone metabolites is instrumental in assessing the effectiveness of Methadone therapy. Methadone metabolite levels provide an empirical measure of the medication's impact, allowing healthcare providers to gauge whether patients are receiving an appropriate dosage for pain management or addiction treatment. This insight is invaluable in fine-tuning treatment regimens to ensure optimal results. 4. Validation of Patient Adherence Methadone metabolite measurement corroborates patient adherence to prescribed Methadone regimens. Discrepancies in metabolite levels may signify non-compliance or misuse, alerting healthcare providers to potential challenges in patient adherence. This knowledge empowers clinicians to tailor interventions and support strategies accordingly. 5. Tailoring Therapeutics through Metabolite Analysis The quantification of Methadone metabolites facilitates the customization of treatment plans. By aligning Methadone dosages precisely with individual patient requirements, healthcare providers optimize therapeutic outcomes while minimizing the risk of adverse effects or overdose. This personalized approach exemplifies the principles of precision medicine. 6. Detection of Diversion and Misuse Within the context of opioid addiction treatment, Methadone metabolite testing serves as a vigilant sentinel against diversion and misuse. By measuring metabolite levels, healthcare providers can identify cases where Methadone is not being used for its intended purpose. This is pivotal in ensuring the medication remains dedicated to the treatment of addiction, minimizing its potential for illicit use. 7. Forensic and Legal Implications Beyond clinical applications, Methadone metabolite analysis assumes paramount significance in forensic and legal domains. It substantiates evidence of Methadone use, playing a central role in legal proceedings, workplace drug testing, and other scenarios where the verification of Methadone exposure is required. 8. Conclusion: Methadone Metabolites in IVD - Paving the Way for Informed Decision-Making In conclusion, Methadone metabolites are integral components of IVD, enhancing the precision and effectiveness of Methadone therapy. Their measurement empowers healthcare providers to assess treatment efficacy, validate patient adherence, and avert potential misuse. Additionally, in legal and forensic contexts, Methadone metabolite analysis offers critical insights into Methadone use, fostering informed decision-making and reinforcing the integrity of therapeutic interventions. Methadone metabolites, in their multifaceted role, continue to shape the landscape of IVD, ensuring that Methadone-based treatments are optimized for patient welfare.

About GDU